Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

NUVB earnings analysis

Filed May 4, 2026 · Our reading of the company's report

The latest report

Nuvation Bio reported Q1 2026 results with significant revenue growth, reflecting a strong commercial launch of its product IBTROZI. Total revenue surged to $83.2 million from just $3.1 million in Q1 2025, driven…

Read full summary

Nuvation Bio reported Q1 2026 results with significant revenue growth, reflecting a strong commercial launch of its product IBTROZI. Total revenue surged to $83.2 million from just $3.1 million in Q1 2025, driven primarily by product sales. However, diluted EPS decreased to $0.01 from $0.16 year-over-year, indicating ongoing financial challenges amid rising operating costs.

Read the original on SEC.gov

Where revenue came from

The business segments reported by the company.

Collaboration revenue 77.8% Product revenue 22.2%

Shares of the segments disclosed in this filing, largest first.

Reported figures

Earnings per share
$0.01

What stood out

  • Revenue Surged by 2,596% YoY

    Nuvation reported $83.2 million in total revenue, up from just $3.1 million in Q1 2025.

  • Commercial Launch of IBTROZI

    Product revenue from IBTROZI was approximately $18.5 million in Q1 2026 following its FDA approval.

  • Collaboration Revenue Increased

    Collaboration and license agreements revenue rose by $61.6 million, mainly from an upfront payment under the Eisai agreement.

  • Operating Cash Flow Positive

    Generated cash provided by operating activities of $5.1 million in Q1 2026.

  • Strong Cash Position

    Ended Q1 2026 with $533.7 million in cash and marketable securities.

  • Deficit Management Strategy in Place

    Management noted ongoing challenges but emphasized the strategy to maintain operations through potential funding.

What to watch

  • Wider Losses Despite Revenue Growth

    Net loss increased to $40 million for Q1 2026, reflecting higher research and development expenses and operational costs.

  • Dependence on IBTROZI Performance

    Future revenue heavily relies on successful commercialization of IBTROZI and market acceptance.

  • Regulatory Compliance Risks

    Navigating complex Chinese data privacy laws poses a potential risk affecting international operations.

Management's outlook

Outlook for the second quarter anticipated to be discussed during the upcoming earnings call.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.